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ABSTRACT 
Objectives To identify predictors of remission and disease activity patterns in patients with 
rheumatoid arthritis (RA) using individual participant data (IPD) from clinical trials.  
Methods Phases II and III clinical trials completed between 2002 and 2012 were identified by 
systematic literature review and contact with UK market authorisation holders. Anonymised baseline 
and follow-up IPD from non-biological arms were amalgamated. Multiple imputation was used to 
handle missing outcome and covariate information. Random effects logistic regression was used to 
identify predictors of remission, measured by the DAS28 score  at 6 months. Novel latent class mixed 
models characterised DAS28 over time. 
Results IPD of 3290 participants from 18 trials were included. Of these participants, 92% received 
methotrexate (MTX). Remission rates were estimated at 8.4% (95%CI: 7.4%-9.5%) overall, 17% 
(95%CI: 14.8%-19.4%) for MTX-naïve early RA patients, and 3.2% (95%CI: 2.4%-4.3%) for those with 
prior MTX exposure at entry. In prior MTX-exposed patients, lower baseline DAS28 and MTX-re-
initiation were associated with remission. In MTX-naïve patients, being young, white, male, with 
better functional and mental health, lower baseline DAS28 and receiving concomitant 
glucocorticoids were associated with remission. Three DAS28 trajectory sub-populations were 
identified in MTX-naïve and MTX-exposed patients. A number of variables were associated with sub-
population membership and DAS28 levels within sub-populations.  
Conclusions Predictors of remission differed between MTX-naïve and prior MTX-exposed patients at 
entry. Latent class mixed models supported differential non-biologic therapy response, with three 
distinct trajectories observed in both MTX-naïve and MTX-exposed patients. Findings should be 
useful when designing future RA trials and interpreting results of biomarker studies.  
 
  
   
Key messages 
What is already known about this subject? 
 Clinical remission is achieved in only a minority of rheumatoid arthritis patients and 
sustained drug-free remission remains rare. Additionally response to treatment varies in 
rheumatoid arthritis. 
What does this study add? 
 Through industry-academic collaboration, individual patient-level data on 3290 patients 
from the non-biological arms of 18 trials were collated and resulted in the identification of 
predictors of remission and longitudinal disease activity patterns. 
 Differential effects of physical/functional and mental well being on 6-month DAS28 
remission  were seen between methotrexate-naïve early disease patients and those with 
established disease and prior methotrexate exposure at entry. 
 Through novel latent class methodology, three longitudinal patterns of disease activity 
were discerned  in both the baseline methotrexate-naïve and methotrexate-exposed 
rheumatoid arthritis patient groups. 
How might this impact on clinical practice? 
 Latent class methodology allows both prediction of trajectory membership and future 
disease course using outcome and covariate information, and can  inform trial selection 
and patient management.  
 BACKGROUND 
Rheumatoid arthritis (RA), an inflammatory disease of synovial joints, leads to functional disability 
and reduced quality of life. Currently, there is no cure but many studies confirm the benefit of early 
and intensive treatment on long-term outcome.(1;2) Nonetheless, clinical remission is achieved in 
only a minority of patients(3;4) and sustained drug-free remission remains rare.(5;6) 
Response to treatment varies in RA.  Clinical trials report average disease activity change, but within 
treatment arms there is heterogeneity; some patients entering clinical remission and some failing to 
respond. Background disease activity also fluctuates, with some patients demonstrating an initial 
short-term improvement then either relapsing or plateauing with still relatively active disease 
irrespective of treatment. Moreover, conventional synthetic disease modifying anti-rheumatic drugs 
(csDMARDs) have slow onset of action. Given that prolonged periods of uncontrolled disease activity 
lead to joint damage and disability, a major unmet need is to identify patient-level predictors of 
response in order to identify patients with differing patterns of response over time (i.e. types of 
patients with a greater or lesser chance of responding).  Such information could guide treatment 
choices, saving both time and money in achieving sustained disease control; and improve the 
efficiency of clinical trials.  
The Rheumatoid Arthritis (RA-MAP) Consortium is a UK industry-academic partnership funded jointly 
by the Medical Research Council (MRC) and the Association of the British Pharmaceutical Industry 
(ABPI). RA-MAP’s goal is to investigate clinical and biological predictors of disease outcome in RA, by 
bringing together experts in basic, clinical, therapeutic development and biostatistical research(7). 
One RA-MAP work-stream investigated clinical predictors of remission and response by collation of 
individual patient-level data (IPD) from the non-biological arms of randomised controlled clinical 
trials (RCTs). The aims were to identify predictors of response and to identify disease trajectory sub-
populations; and then use the findings to inform study design and analysis of future studies.  
METHODS 
Identification of relevant studies and study selection 
Potential studies were identified by systematic literature review (final search: 13th March 2012) from 
MEDLINE, EMBASE, PubMed, Ovid, Web of Science, UK Clinical Research Network Portfolio Database 
(http://public.ukcrn.org.uk/), ClinicalTrials.gov (https://clinicaltrials.gov) and the National Research 
Register. Searches combined MeSH terms for RA, study type (e.g. ‘randomised controlled trial’) and 
biologic and non-biologic DMARDs . Additionally, Chief Investigators of known academic-led clinical 
trials completed between 2002 and 2012, involving UK patients, were contacted. Current UK market 
authorisation holders for non-biological and biological DMARDs were also sent a survey via their RA-
MAP representative to identify additional trials and seek information on availability of IPD from 
clinical trials co-ordinated in the UK or which enrolled UK subjects. 
Assessment of trials’ eligibility for inclusion was performed independently by the Study Coordinator 
and Principal Investigator (DPMS). Lack of consensus was resolved through discussion with the trial’s 
Chief Investigator(s), industry sponsor or referral to study publications.  
A second literature search was conducted to identify known predictors of remission in RA.  This 
informed the request for baseline data items. 
Owners of suitable trial data-sets were approached via the RA-MAP representative for access to data 
on requested variables for all (or a random 80% of) participants in non-biologic arm(s) of these trials. 
The inclusion criteria, trials obtained and data requested are detailed in supplementary information. 
Eligibility of datasets relied on the original informed consent allowing data sharing. 
Data collection, management and harmonisation 
De-identified data were transferred to the Co-ordinating Centre, and further anonymisation added 
through generation of new unique study identifiers. 
Data received were checked for internal consistency, with queries referred back to data 
owner/supplier. Data were harmonised across trials (i.e. given single variable name, standardisation 
of unit measurement, similar coding of variables when possible) to a standard format for 
incorporation into a central database. The end product was a pooled database of IPD from trials 
received.  Although a common set of items was requested, some trials, by design, had not collected 
all items, or when collected, differed in form/construct or level of detail. 
Derived disease activity measure and remission definition 
Where possible DAS28 score was derived using the four individual components of erythrocyte 
sedimentation rate (ESR) (mm/hr), patient global assessment of disease activity (0-100mm visual 
analogue scale [VAS]), 28-tender and 28-swollen joint counts.(8) If patient global assessment was 
not supplied as a VAS, the three-component DAS28 was calculated.(8) If direct derivation of DAS28 
was not possible then supplied DAS28 was used or the transformation of van Gestel et al.(9) applied 
to convert original DAS(10;11) to DAS28. Clinical remission was defined as DAS28 < 2.6.(12)   
Sample size evaluation 
Initial sample size calculation considered a remission model with 25 significant effects. For simplicity, 
it assumed that these effects arose from continuous variables that remained statistically significant 
when dichotomised. A clinically worthwhile detectable difference in remission rates between two 
groups, formed by median dichotomisation of any predictor, was taken as 4% (e.g. 6% remission rate 
for group below median versus 10% for group above median; giving an overall remission rate of 8%). 
Assuming a significance level of 0.2% (accounting for multiple testing), a total sample size of 4218 or 
2942 is calculated for 95% or 80% power respectively.  
The above scenario was conservative because (i) fewer significant effects could be expected; (ii) 
dichotomisation results in efficiency losses; (iii) a 4% difference was considered small; and (iv) strict 
significance level of 0.2% was chosen. It was anticipated that sample sizes above 2500 would be 
sufficient to achieve the work-stream’s aims.  
Statistical methods 
The main analyses were based on co-primary outcomes of clinical remission at 6 months (within a 22 
to 26 week-window) and DAS28 measured longitudinally. One trial, with 12-week follow-up, was 
excluded from analyses of remission at 6 months but included in analyses of DAS28 over time. 
Clinical remission was estimated overall, and separately for methotrexate-naïve (MTX-naïve) entry 
subjects and those with prior MTX exposure (MTX-exposed).  The MTX-exposed group consisted of 
those on background MTX at trial entry and those who had discontinued MTX. 
To identify predictors of remission, (multi-level) random effects logistic regression models (with trial-
level random effects) stratified by baseline MTX exposure were considered. If heterogeneity across 
trials was insubstantial then trial-level random effects were removed. The base model focussed on 
known predictors of remission and potential confounders with limited missing information.(13-15) It 
considered the effect of age, sex, ethnicity, disease duration, DAS28, rheumatoid factor (RF) status, 
and RA medication (both prior exposure and as part of study treatment protocol) at baseline. 
Baseline DAS28 and history of RA medication were also included to adjust for differences in the trial 
populations due to differing inclusion criteria. Screening models considered separate effects of other 
potential baseline predictors introduced into the base model. Multivariate models were then built 
using variables identified as important at screen and forward selection.   
Longitudinal latent class mixed models, stratified by MTX exposure at baseline, were used to (i) 
characterise DAS28 over time (restricted to one year follow-up), (ii) adjust for potential predictors, 
(iii) incorporate within-patient correlation, and (iv) identify cluster trajectories of clinically important 
sub-populations.(16) Fixed and random patient-level intercepts, linear and quadratic effects were 
considered for linear mixed models fitted within latent classes. These random effects were nested 
within trial. Trial-level random effects were considered, but removed when found inconsequential. 
(Relative) entropy was calculated to assess the ability of each model to classify individuals into latent 
classes.(17) Higher values of entropy indicate better classification of individuals.  
Sporadically and systematically missing baseline covariate and missing outcome information at 
attended visits were imputed using multivariate imputation by chained equations (MICE),(18;19) 
under the missing at random assumption. The hierarchical/multi-level structure (i.e. visits within 
patient, patients within trial) was respected where possible. Twenty imputed data-sets were 
created, analysed and results pooled using Rubin’s rules.(20)  
All statistical analyses were performed in R statistical software.(21) R packages, lme4,(22)  mice,(23) 
and lcmm(24) were used for the various analyses. 
RESULTS 
Systematic search and inventory of trials survey 
We identified 63 trials to include in the inventory (Supplementary figure 1). Sixty trials were 
industry-sponsored (54 from RA-MAP partners) and 3 academic (from RA-MAP partners). Partial or 
complete information from study sponsors or publicly available sources was collated for 54/63 trials. 
There were 8778 patients in non-biological arms of these 54 trials with estimated 6-month remission 
rate of 8.2%. This estimate informed study sample size (see Methods section).  
Trials received 
Patient-level data from non-biological arms of 19 trials were provided by six industry and two 
academic RA-MAP partners (see Supplementary Tables 1a and 1b). One trial was excluded as it 
recruited patients with early inflammatory polyarthritis. Patients in the included trials (all started  
Table 1: Baseline characteristics of patients in 18 trials, overall (N=3290) and stratified by methotrexate (MTX) status 
prior to randomisation (i.e. MTX-naive (N=1137) and MTX-exposed (N=2148); in 5 patients MTX status was unknown) 
** Not mutually exclusive categories as patients can be randomised to or receive dual therapy 
before 2010) met the 1987 American College of Rheumatology (ACR) RA classification criteria.(25)  
Data for 3290 participants from the combined non-biological arms of these 18 trials were obtained. 
Patient numbers from these trials ranged from 50 to 467. Non-biological assigned treatments 
included (i) placebo, (ii) MTX or other csDMARD monotherapy, or (iii) MTX in combination with 
another csDMARD and/or with glucocorticoid. Placebo treated patients received either (i) placebo in 
addition to background RA medication; (ii) placebo alone (with RA medication discontinued prior to 
trial start); or (iii) placebo alone (with no prior RA medication, i.e. RA-medication naïve). Further 
information on planned duration of RCT phase, inadequate response to csDMARDs, biological 
intervention, primary and secondary efficacy outcomes related to disease activity are reported in 
Supplementary Tables 1a and 1b.  No data on patients treated in the biological arms of these trials 
were requested or received. 
Patient Characteristics 
The baseline demographic and disease characteristics of included patients are summarised in Table 
1. Only three trials provided information on anti-citrullinated protein antibody (ACPA) status. The 
mean baseline DAS28 (with standard deviation) was 6.5 (1.1).  
Fifty four percent of patients were on background MTX at start, 35% were MTX-naïve, and 11% had 
prior MTX exposure (MTX discontinued). Ninety two percent of participants were either randomised 
to MTX or were on background MTX that continued. Twelve percent were randomised to or 
continued other csDMARDs.  The corresponding percentage for glucocorticoids was 27%. The 
majority of MTX-naïve patients at entry (93%) were randomised to MTX. Fifty two percent of those 
Characteristics No. of trials 
with info 
Overall (N=3290) MTX-naïve (N=1137) MTX-exposed (N=2148) 
  Value % Miss Value  % Miss Value  % Miss 
Mean age (SD), years 18 52.6 (12.6) 0 52.7 (13.1) 0 52.6 (12.4) 0 
Female, % 18 79 0 73.6 0 81.8 0 
White, % 18 85.7 0.9 89.3 0.09 83.8 1.3 
Rheumatoid factor positive, % 18 75.3 1.8 76.3 3.5 76.6 0.6 
Median (IQR) disease duration, years 17 4 (1-10) 5.6 0.67 (0-1.5) 1.8 7 (3-13) 7.7 
Mean (SD) age at onset, years 18 46 (13.6) 5.6 50.6 (13.5) 1.8 43.5 (13.0) 7.7 
Smoking Status, % 
Non-smoker 
Current Smoker 
Not current/Ex-Smoker 
10  
14.9 
19.2 
65.9 
39.3  
26.5 
22.4 
51.1 
57.2  
11.1 
18.2 
70.7 
29.7 
Mean (SD) 28-tender joint count 16 15.1 (7.1) 9.6 13.6 (7.6) 14.2 15.8 (6.8) 7.2 
Mean (SD) 28-swollen joint count 16 12.3 (6) 9.6 11.4 (6.3) 14.2 12.8 (5.7) 7.2 
Mean (SD) erythrocyte sedimentation rate (ESR), mm/hr 18 46.2 (27) 0.5 44.1 (27.7) 0.18 47.4 (26.5) 0.7 
Mean (SD) C-reactive protein (CRP), mg/dl 17 2.64 (3.3) 16.3 3.285 (3.399) 44.1 2.44 (3.24) 1.6 
Mean (SD) DAS28 (using ESR) 18 6.5 (1.1) 1.7 6.25 (1.20) 1.1 6.613 (0.939) 2.0 
Mean (SD) HAQ 12 1.578 (0.640) 21.3 1.588 (0.663) 2.6 1.571 (0.622) 31.1 
Mean (SD) SF-36 Physical Summary Score 12 30.73 (7.73) 24.4 29.95 (8.10) 17.9 31.2 (7.5) 27.7 
Mean (SD) SF-36 Mental Summary Score 12 41 (12.31) 24.4 40.84 (13.33) 17.9 41.1 (11.7) 27.7 
Methotrexate (MTX) History Status, % 
MTX-Naïve 
On Background MTX (ongoing) 
Previous MTX use (stopped) 
18  
34.6 
54.2 
11.2 
0.2    
0 
82.9 
17.1 
0 
Randomised to or on MTX at start, %**  18 92.1 0 93.1 0 91.8 0 
Randomised to or on csDMARD (other than MTX)  at start, %** 18 11.9 0 25.2 0 5 0 
Randomised to Glucocorticoids at start, %** 18 7  0 20.3  0 0  0 
Randomised to or on Glucocorticoids at start, %** 18 27.4 0 28.4 0 27 0 
who discontinued MTX were randomised to MTX re-initiation.  A majority of them were viewed as 
having already demonstrated lack of adequate MTX response. 
The 1137 patients who were MTX-naïve at trial entry had substantially shorter median symptom 
duration than the 2148 patients with prior MTX-exposure (8 months vs 7 years p<0.0001); 
confirming the fact that the former corresponded to those with early RA.  
Table 2: Final logistic regression models A (including SF-36 summary scores to base model) and B (including HAQ to base 
model) for clinical remission at 6 months for MTX-naive subjects at entry 
Predictors log(OR) Standard Error 
of log(OR) 
Odds Ratio 
(OR) 
95% CI 
for OR 
p-value 
Final Model A  (inclusion of SF-36 summary  
components to base model) 
     
Intercept* ---- ---- ---- ---- ---- 
Age at Entry, years -0.0249 0.0076 0.98 0.96-0.99 0.0010 
Disease Duration, years -0.0033 0.0300 1.00 0.94-1.06 0.9125 
Gender                                                       Male v Female 0.9793 0.1953 2.66 1.82-3.90 <0.0001 
Ethnicity                                                         White v Rest 1.3489 0.4957 3.85 1.46-10.2 0.0065 
DAS28-ESR at Baseline -0.3616 0.0891 0.70 0.58-0.83 <0.0001 
Rheumatoid Factor Positivity                            Yes v No -0.1352 0.2016 0.87 0.59-1.30 0.5024 
Randomised to MTX at start*                           Yes v No ---- ---- ---- ---- ---- 
Randomised to or on csDMARD at start         Yes v No 0.1809 0.2726 1.20 0.70-2.04 0.5070 
Randomised to Glucocorticoids at start          Yes v No 1.3375 0.2926 3.81 2.15-6.76 <0.0001 
On Background Glucocorticoids at start         Yes v No 0.2478 0.4857 1.28 0.49-3.32 0.6099 
SF-36 Physical Summary Score 0.0423 0.0118 1.04 1.02-1.07 0.0003 
SF-36 Mental Summary Score 0.0209 0.0076 1.02 1.01-1.04 0.0063 
Final Model B (Inclusion of HAQ to base model)      
Intercept* ---- ---- ---- ---- ---- 
Age at Entry, years -0.0191 0.0075 0.98 0.97-1.00 0.0109 
Disease Duration, years -0.0032 0.0299 1.00 0.94-1.06 0.9157 
Gender                                                      Male v Female 0.8551 0.1945 2.35 1.61-3.44 <0.0001 
Ethnicity                                                       White v Rest 1.3756 0.4937 3.96 1.50-10.4 0.0053 
DAS28-ESR at Baseline -0.3489 0.0904 0.71 0.59-0.84 0.0001 
Rheumatoid Factor Positivity                           Yes v No -0.1352 0.2008 0.87 0.59-1.29 0.5009 
Randomised to MTX at start*                          Yes v No ---- ---- ---- ---- ---- 
Randomised or on csDMARD at start             Yes v No 0.1789 0.2714 1.20 0.70-2.04 0.5097 
Randomised to Glucocorticoids at start        Yes v No 1.3976 0.2920 4.05 2.28-7.17 <0.0001 
On Background Glucocorticoids at start        Yes v No 0.3778 0.4829 1.46 0.57-3.76 0.4340 
HAQ -0.6325 0.1616 0.53 0.39-0.73 <0.0001 
* Estimates and standard error are not estimable. MTX usage during study has been adjusted for in models. Majority of MTX-naïve 
subjects at trial entry received MTX during study (93%). 
Clinical remission at 6 months 
Overall 6-month remission rate was estimated at 9.6% (95%CI: 8.4%-10.9%) based on 2275 patients 
for whom 6-month remission could be defined from observed data. After multiple imputation, a 6-
month remission rate of 8.4% (95%CI: 7.4%-9.5%) was estimated based on 2766 patients who had 
attended visits within the 22-26 weeks window period. For MTX-naïve entry participants, observed 
6-month remission rate was 17.7% (95%CI: 15.4%-20.2%) and estimated remission rate after 
imputation was 17% (95%CI: 14.8%-19.4%) based on 1048 patients. For MTX-exposed patients, 
corresponding estimates were 3.5% (95%CI: 2.6%-4.6%) and 3.2% (95%CI: 2.4%-4.3%) based on 
observed data and imputed data from 1718 patients. The adjusted odds ratio of achieving 6-month 
remission for MTX-exposed versus MTX-naïve patients was 0.26 (95%CI: 0.17-0.40). Adjustments 
were made for variables included in the base logistic regression model.  
Predictors of clinical remission at 6 months 
MTX-naïve at entry 
The base (multi-level) random effects logistic regression model for MTX-naïve entry patients is 
shown in Supplementary Table 2. Age, sex, ethnicity, baseline DAS28, and randomised to 
concomitant glucocorticoids were associated with remission.  After screening, three additional 
variables were considered in building the model further. These were functional disability (HAQ), SF-
36 Physical and Mental Summary Scores. 
As HAQ was negatively correlated with SF-36 Physical Summary Score (Pearson correlation of -0.57), 
two final models (A and B; see Table 2) were derived, in which either HAQ or SF-36 Physical 
Summary Score (but not both together), alongside the SF-36 Mental Summary Score, were 
considered for inclusion using forward selection. In these models, remission was predicted by being 
white, male, younger, randomised to concomitant glucocorticoids, having better functional/physical 
and mental health and lower DAS28, at baseline. Being randomised to concomitant glucocorticoids 
increased the odds of achieving remission by 4.0 (95%CI: 2.3-7.2) over not receiving glucocorticoids 
(Model B), controlling for other variables. As most MTX-naïve entry subjects (93%) received MTX, an 
effect for receiving MTX during the trial could not be estimated, although it was adjusted for in the 
analysis. 
Table 3: Final logistic regression model for clinical remission at 6 months for MTX-exposed subjects 
Predictors log(OR) Standard 
Error of OR 
Odds Ratio 
(OR) 
95% CI 
for OR 
p-value 
Intercept ---- ---- ---- ---- ---- 
Age at Entry, years -0.0160 0.0124 0.98 0.96-1.01 0.1953 
Disease Duration, years -0.0105 0.0206 0.99 0.95-1.03 0.6109 
Gender                                                                                 Male v Female 0.2935 0.3697 1.34 0.65-2.77 0.4271 
Ethnicity                                                                                  White v Rest -0.0511 0.4137 0.95 0.42-2.14 0.9017 
DAS28-ESR at Baseline -0.8228 0.1600 0.44 0.32-0.60 <0.0001 
Rheumatoid Factor Positivity                                                     Yes v No -0.5277 0.3214 0.59 0.31-1.11 0.1007 
MTX use in trial 
(Randomised to MTX, Previous use) v (Not receiving, Previous use) 
Background MTX continued v (Not receiving, Previous use) 
 
1.6499 
0.0126 
 
0.8252 
0.7874 
 
5.21 
1.01 
 
1.03-26.2 
0.22-4.74 
 
0.0456 
0.9873 
Randomised to or on csDMARD at start                                    Yes v No  1.1721 0.8953 3.23 0.56-18.7 0.1905 
On Background Glucocorticoids at start                                    Yes v No 0.1169 0.3299 1.12 0.59-2.15 0.7230 
 
MTX-exposed at entry 
The logistic regression (dropping trial-level random effects) in MTX-exposed patients (see Table 3) 
identified lower baseline DAS28 and randomisation to MTX as being associated with achieving 6-
month remission. However, patients with prior MTX exposure who were randomised to MTX re-
initiation were significantly more likely (p<0.0001) to achieve remission than those continuing on 
background MTX (adjusted odds ratio (OR) 5.2 with 95%CI: 2.5-10.4). No evidence for 
functional/physical and mental health effects was found. 
Characterising disease activity over one year of follow-up 
Novel latent class mixed modelling of DAS28 suggested the clustering into three sub-
populations/classes with differing trajectory profiles in both MTX naïve and exposed baseline 
groups. No evidence to support inclusion of trial-level random effects, random slopes or random 
quadratic effects was found and so the linear mixed models within latent classes contained only 
fixed effects and random intercepts. 
MTX-naïve at entry 
The three sub-populations identified (Table 4 and Figure 1a; N=1137) corresponded to a fast 
improver group (Class 1; 8% of patients) who, on average, started with higher DAS28; a moderate 
Table 4: Latent Class Mixed Model Results for MTX-naïve entry subjects over 1-year follow-up 
Predictors log(OR) Standard Error of OR p-value 
Multinomial Class Membership Model    
Class 1 (Fast Improver) v Class 2 (Moderate Improver)    
    Intercept -2.1947 0.4901 <0.0001 
    Sex                                                                                                     Male v Female 0.8881 0.3065 0.0038 
    Baseline HAQ 0.3416 0.2902 0.2393 
Class 3 (Inadequate Response) v Class 2 (Moderate Improver)    
    Intercept -1.2339 0.6461 0.0561 
    Sex                                                                                                     Male v Female 0.0128 0.2762 0.9629 
    Baseline HAQ 0.6174 0.2805 0.0277 
Linear Mixed Model Estimate Standard Error p-value 
    Intercept  
Class 1 
Class 2 
Class 3 
 
7.788 
5.6199 
5.7350 
 
0.9264 
0.3158 
0.3400 
 
<0.0001 
<0.0001 
<0.0001 
    Disease Duration, years 
Class 1 
Class 2 
Class 3 
 
-0.0083 
-0.0016 
0.0312 
 
0.0397 
0.0104 
0.0126 
 
0.8335 
0.8768 
0.0136 
    Ethnicity 
White v Rest   Class 1 
White v Rest   Class 2 
White v Rest   Class 3 
 
-0.5313 
-0.2726 
-0.4331 
 
0.3882 
0.1837 
0.1719 
 
0.1711 
0.1379 
0.0118 
    Follow-up Time in Study, weeks  
Class 1 
Class 2 
Class 3 
 
-0.2051 
-0.1117 
-0.0420 
 
0.0221 
0.0080 
0.0080 
 
<0.0001 
<0.0001 
<0.0001 
    Follow-up Time squared 
Class 1 
Class 2 
Class 3 
 
0.0025 
0.0014 
0.0006 
 
0.0004 
0.0001 
0.0002 
 
<0.0001 
<0.0001 
<0.0001 
    Randomised to MTX at start 
Yes v No   Class 1 
Yes v No   Class 2 
Yes v No   Class 3 
 
-1.2085 
-0.1143 
-0.1299 
 
0.8352 
0.2230 
0.2181 
 
0.1479 
0.6082 
0.5513 
    Randomised or on csDMARD at start 
Yes v No   Class 1 
Yes v No   Class 2 
Yes v No   Class 3 
 
-0.0597 
-0.1673 
-0.1127 
 
0.4436 
0.1304 
0.1303 
 
0.8930 
0.1993 
0.3871 
    Randomised to Glucocorticoids at start 
Yes v No   Class 1 
Yes v No   Class 2 
Yes v No   Class 3 
 
-0.3899 
-0.3962 
-0.2540 
 
0.3976 
0.1480 
0.1550 
 
0.3267 
0.0074 
0.1013 
    On Background Glucocorticoid at start 
Yes v No   Class 1 
Yes v No   Class 2 
Yes v No   Class 3 
 
-0.4879 
0.2907 
0.3468 
 
0.3389 
0.2262 
0.2123 
 
0.1500 
0.1987 
0.1024 
    HAQ (time-varying) 
Class 1 
Class 2 
Class 3 
 
0.4913 
0.5564 
0.6114 
 
0.1045 
0.0698 
0.1035 
 
<0.0001 
<0.0001 
<0.0001 
    Variance Components* 
Variance of Random Intercept 
Error Standard Deviation 
 
0.6308 
0.7941 
 
0.0506 
 0.0122 
 
<0.0001 
<0.0001 
    Relative Entropy+  0.758   
* Trial-levels random effects were investigated and found to be not necessary 
+ A relative entropy takes values between 0 and 1, with 1 indicating perfect classification 
  
Table 5: Latent Class Mixed Model Results for MTX-exposed subjects over 1-year follow-up 
Predictors log(Odds Ratio) Standard Error p-value 
Multinomial Class Membership Model    
Class 1 (Fast Improver)  v Class 2 (Plateaued)    
    Intercept -1.7852 0.3187 <0.0001 
    Baseline HAQ 0.4137 0.2073 0.0460 
Class 3 (Refractory) v Class 2 (Plateaued)    
    Intercept -0.7352 0.2987 0.0138 
    Baseline HAQ 0.5536 0.1648 0.0008 
Linear Mixed Model Estimate Standard Error p-value 
    Intercept  
Class 1 
Class 2 
 Class 3 
 
5.2433 
5.7507 
5.8371 
 
0.6394 
0.2552 
0.2018 
 
<0.0001 
<0.0001 
<0.0001 
    Ethnicity 
White v Rest   Class 1 
White v Rest   Class 2 
White v Rest   Class 3 
 
-0.1746 
-0.2380 
-0.1233 
 
0.1929 
0.1034 
0.0931 
 
0.3655 
0.0213 
0.1852 
    Follow-up Time in Study, weeks  
Class 1 
Class 2 
Class 3 
 
-0.1668 
-0.0863 
-0.0030 
 
0.0091 
0.0059 
0.0042 
 
<0.0001 
<0.0001 
0.4697 
    Follow-up Time Squared 
Class 1 
Class 2 
Class 3 
 
0.0021 
0.0014 
0.0001 
 
0.0001 
0.0001 
0.0001 
 
<0.0001 
<0.0001 
0.1708 
    MTX use 
(Rand MTX, prev on) v prev on but not rand    Class 1 
(Rand MTX, prev on) v prev on, but not rand    Class 2 
(Rand MTX, prev on) v prev on, but not rand    Class 3 
Background MTX continued v prev on but not rand    Class 1 
Background MTX continued v prev on but not rand    Class 2 
Background MTX continued v prev on but not rand    Class 3 
 
1.0513 
0.0186 
0.3206 
0.9683 
0.0762 
0.5088 
 
0.6129 
0.2750 
0.2381 
0.6140 
0.2430 
0.1729 
 
0.0863 
0.9461 
0.1781 
0.1148 
0.7539 
0.0032 
    Randomised or on csDMARD at start 
Yes v No   Class 1 
Yes v No   Class 2 
Yes v No   Class 3 
 
0.5336 
-0.1657 
0.6739 
 
0.6840 
0.3004 
0.2151 
 
0.4353 
0.5813 
0.0017 
    On Background Glucocorticoids at start 
Yes v No   Class 1 
Yes v No   Class 2 
Yes v No   Class 3 
 
-0.1578 
0.0648 
-0.1037 
 
0.1551 
0.0843 
0.0788 
 
0.3088 
0.4419 
0.1885 
    HAQ (time-varying) 
Class 1 
Class 2 
Class 3 
 
0.3958 
0.3773 
0.2641 
 
0.0601 
0.0413 
0.0313 
 
<0.0001 
<0.0001 
<0.0001 
    Variance Components 
Variance of Random Intercept 
Error Standard Deviation 
 
0.6174 
0.6902 
 
0.0269 
0.0056 
 
<0.0001 
<0.0001 
    Relative Entropy+ 0.609   
* Trial-levels random effects were investigated and found to be not necessary 
+ A relative entropy takes values between 0 and 1, with 1 indicating perfect classification 
  
improver group (Class 2; 31.6%) who improved at around half the rate of fast improvers; and an 
inadequate responder group (Class 3; 60.4%) with an improvement rate only 20% of that in Class 1. 
On average, a typical RA patient’s DAS28 would improve by 3.91 in the fast improvers; 2.02 in 
moderate improvers; and 0.56 in inadequate responders over 1 year of follow-up from trial entry. 
Higher baseline HAQ was associated with having inadequate response. Men were more likely than 
women to be fast improvers compared to moderate improvers.  Higher DAS28 over time in 
inadequate responders was associated with longer symptom duration (p=0.0136), non-white 
(p=0.0118) and higher HAQ over time (p<0.0001). In moderate improvers, not being randomised to 
glucocorticoids (p=0.0074) and higher HAQ over time (p<0.0001) were associated with higher DAS28.  
In fast improvers, only higher HAQ was associated with higher DAS28 (p<0.0001). The model’s 
entropy was 0.758, demonstrating good classification. A four-latent class model with the same 
variables gave lower entropy (0.711). 
MTX-exposed at entry 
The three sub-populations identified (Table 5; Figure 1b; N=2148) corresponded to a fast improver 
group (Class 1; 9.4% of patients), although not as fast as the corresponding MTX-naïve sub-
population; a group that showed initial improvement but then plateaued and slowly worsened (Class 
2; 43.4%); and a refractory group (Class 3; 47.3%). On average, a typical RA patient’s DAS28 would 
improve by 3 in the fast improvers; 0.7 in the plateauing group; and would worsen by 0.11 in those 
refractory over 1 year of follow-up.  
The “plateauing” group tended to include, on average, patients with lower baseline functional 
disability. Moreover, in this group, there was evidence to suggest that higher DAS28 associated with 
being non-white (p=0.0213). Worsening DAS28 was associated with worsening functional disability 
over time, irrespective of sub-population.  In the refractory group, continuation of background MTX 
or receiving other csDMARDs as an initial treatment at trial entry was, on average, associated with 
increased disease activity (DAS28 increase of 0.51, p=0.0032 and 0.67, p=0.0017 respectively) over 
time.  
The model’s entropy was 0.609, demonstrating modest classification. A four-latent class model 
identified an additional group (around 3.3% of patients), that showed rapid improvement over three 
months and then rebounded dramatically. Although this model had increased entropy (0.659), given 
the fourth group’s size and unusual pattern, the three-latent class model was preferred. 
Model outputs 
The models presented in Tables 4 and 5 are useful for characterising disease activity over time into 
more homogeneous sub-populations and for identifying predictors of sub-population membership 
and disease activity level.  The models are also useful for calculating and updating the probabilities 
of a patient belonging to each of the sub-populations given their current value of DAS28 and 
covariates and estimated parameters from the model (including estimated random patient-level 
effects).(24) This would be particularly useful in an adaptive trial as a new individual recruited could 
be assigned probabilities of belonging to each trajectory by a model that included all previously 
recruited individuals.  
Furthermore such models also allow subject-specific predictions of future DAS28 values for patients 
either given a particular trajectory sub-population or averaged over all possible trajectory sub-
populations. They would also allow population-averaged inference for particular subgroups of 
patients defined by the values of baseline covariates to inform, for example, national treatment 
guidelines for RA patients. 
DISCUSSION 
By means of a large industry-academic partnership, IPD from non-biologic arms of 18 RA RCTs were 
amalgamated. These data on 3290 patients allowed a more definitive investigation into clinical 
predictors of remission, beyond a systematic literature review, through flexible multivariate 
modelling and novel subgroup analyses using latent class mixed modelling methodology. 
We did not aim to do an IPD meta-analysis in order to estimate a common treatment effect across 
multiple trials investigating the same treatment against the same control intervention. Instead our 
goal was to treat this IPD study as an observational cohort in order to more comprehensively 
investigate the predictors of remission on a variety of non-biologic treatments and to discover 
clinically meaningful sub-populations of RA patients that could inform the future recruitment of RA 
patient types into trials and more stratified patient management. 
Although patients in RCTs are generally considered to be poorly representative of those patients 
seen in the general RA clinic population (having higher levels of disease activity at entry and fewer 
and less severe comorbidities), they nevertheless represent a sub-population of RA patients with 
very real clinical need. Additionally, they represent a patient sub-population in which treatment 
management decisions would be made based on the patients’ arthritis symptoms and signs and not 
complicated by comorbidities and the potential for interactions between the assigned treatments 
and the comorbidities.  
We conducted separate analyses for MTX-naïve and MTX-exposed strata at trial entry, reflecting 
relatively early and more established disease respectively. Unsurprisingly, the 6-month remission 
rate for MTX-naïve (majority then randomised to MTX) patients was substantially higher (17% vs 
3.5%) than for those with prior MTX exposure. Utilisation of a treat-to-target strategy, as is usual in 
clinical practice, may have increased the remission rate in this group further. 
A major unmet need is identifying which RA patients are more or less likely to achieve remission. Our 
results suggest that, in MTX-naïve entry patients with relatively early disease and high disease 
activity, baseline factors including age, gender, ethnicity, disease activity, mental health and physical 
functioning may help identify those with a higher or lower chance of achieving 6-month remission. 
Whilst all these factors have been previously identified(14;26;27), we have confirmed them in a very 
large sample with the benefits of controlled trial conditions, not usually achievable with large 
observational studies.  These factors should be considered stratifiers when designing future clinical 
trials and interpreting results of biomarker studies. The potential role of mental health is of current 
interest, although mechanisms are uncertain, complex and bidirectional.(26;28;29) The fact that 
mental and physical/functional well being were predictive in MTX-naïve entry patients with 
relatively early disease but not in the prior MTX-exposed entry patients with more established 
disease is of note and should be explored further as it is difficult in our study to disentangle 
early/established disease from no/previous exposure to MTX. Some previous studies have shown an 
effect of smoking status on disease activity(14;30) we could not confirm this.  However, our finding 
could be due to the high proportion of systematically missing smoking data (57%). RF was not 
associated with remission here. Previous studies show conflicting results.(14;31;32)  
We identified three distinct disease activity trajectories in both MTX-naïve entry and MTX-exposed 
strata.  Although we have given trajectory classes similar names in both strata, the degree of 
improvement differed depending on MTX-exposure history (or early versus established disease at 
entry through confounding).  Siemons et al. (2014) also observed three distinct trajectories from an 
unadjusted latent class mixed model analysis over the first year in early RA patients.(33)  All their 
patients followed a treat-to-target strategy and 82% belonged to a “fast response” group with only 
3% in a “poor response” group. They found evidence for differences across groups in baseline 
disease activity measures, pain, SF-36 physical and mental health summary scores.(33) However, 
they found weaker evidence to support a role of gender in distinguishing groups. We found gender 
and baseline functional disability were predictors of trajectory class in the MTX-naïve group. The 
latter was the lone predictor of class membership for MTX-exposed patients.  However the findings 
of Siemons et al were based on one-way ANOVAs rather than introducing variables into their latent 
class model. There has been debate on whether or not the incorporation of covariates may play an 
important role in enumerating classes.(34)  
A number of variables were associated with DAS28 levels within trajectory classes. In both MTX-
naïve and MTX-exposed patients, higher HAQ was associated with higher DAS28 in all classes.  
Interestingly, in the refractory class of MTX-exposed patients, those who continued background MTX 
or took other csDMARDs at trial start had higher DAS28 over time. In the class which plateaued, non-
whites had higher DAS28 over time. Furthermore, non-whites had higher DAS28 within both 
moderate improver and inadequate response trajectory classes of the MTX-naïve stratum.  
It may seem somewhat confusing that lower disease activity at baseline was associated with 
achieving clinical remission at 6 months in both baseline MTX-naïve and MTX-exposed groups, and 
yet there was a subpopulation of baseline MTX-naïve patients who improved rapidly but started 
with, on average, higher levels of disease activity at baseline than the other two subpopulations of 
MTX-naïve patients. However, when comparing two patients who differ at baseline with regard to 
only disease activity (with all other baseline covariates being the same), it is not surprising that the 
one with the lower baseline disease activity has a higher chance of attaining remission, presumably 
because he/she has less far to go to attain remission.  By comparison, the MTX-naïve subpopulation 
of ‘fast improvers’ who started with the highest levels of disease activity and rapidly improved, 
differed from the other MTX-naïve sub-populations in terms of its gender and HAQ baseline 
distributions. That is, the ‘fast improvers’ had a higher proportion of males and, on average, had 
higher HAQ values than the other subgroups.  Therefore this ‘fast improvers’ group starts off with 
higher levels of disease activity and rapidly improves compared to the others primarily because it 
was made up of patients with a different profile of covariate values in terms of gender and HAQ. It is 
known that high levels of HAQ at baseline correlate positively with high levels of DAS28 at baseline 
and that men are more likely to achieve clinical remission at 6 months than women in the MTX-naïve 
subpopulation (Table 2).  
When interest is focused on early treatment response and its predictors, then approaches which 
restricts the longitudinal disease activity response to this early time period rather than the whole 
follow-up period may be more appropriate. Such approaches would be much more applicable to 
recent clinical trials in early disease in which aggressive treatment reflects the window of 
opportunity and treat-to-target goals. 
There are many advantages to combining data from multiple trials. However, one methodological 
challenge is data harmonization across trials; in particular here, with regards to creating a common 
DAS28 variable. There is ongoing debate as to the exact equivalence of DAS28 calculated using 
different formulae and the validity of combining different methods of calculation in the same 
analysis.  These issues could impact on findings, although we believe less so in characterising disease 
activity over time.  There is also debate over the extent to which DAS28 remission cut-off 
overestimates remission, as defined by absence of residual inflammatory disease activity.(35) 
However, DAS28 remission remains a widely used and aspirational target in clinical practice and 
trials, and we do not believe this invalidates our findings. 
Even though our analyses were done using relatively large sample sizes, there is still the need to 
validate the findings before these results/models could be used to inform clinical practice or trial 
selection. There is a potential for our models to be over optimistic due to the model fitting process 
and multiple testing. In addition, models which incorporate routinely collected biomarkers may have 
more clinical utility.  
The existence of differing trajectories supports a stratified medicine approach and suggests the 
potential for tailoring treatments to distinct patient subpopulations. Moreover, trajectories and 
predictors of response may differ by drug class. For example, these latent class mixed models would 
allow us, using the disease activity measure at screening (or past disease activity measures) and 
baseline covariate information, to estimate the likely trajectory pattern a MTX-naïve patient with 
high disease activity would take if they were to enter a trial and be randomised to a non-biologic 
arm. If it was important, in this trial, to select only patients who had a high probability of responding 
to treatment, then our models could identify those patients who were least likely to respond (i.e. the 
inadequate responders) to the control treatment and exclude them from the trial. These types of 
models could also be used in clinical practice (when validated) for example to assign a probability of 
response to different choices or combinations of csDMARDs by a MTX-naïve patient with active 
disease (assuming that the clinician had access to their past disease activity values and covariate 
information). The prediction of trajectory class or the likely response to a change in treatment could 
be refined at follow-up visits using current disease activity values. 
The entropies of our models, for both MTX-naïve and MTX-exposed strata, show room for 
improvement in classification accuracy.  We anticipate that the addition of novel immune 
biomarkers, being investigated by the RA-MAP consortium through their inception cohort study, will 
lead to predictor models that are clinically informative when choosing treatments for RA patients.  
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Figure Legend: 
Figure 1a: Mean profiles over 1 year from the observed DAS28 data for patients who were MTX-
naïve at trial entry, after stratifying by predicted class membership. Class 1 – Fast Improver Group 
(red): 8%; Class 2 – Moderate Improver Group (blue): 31.6%; Class3 – Inadequate Response Group 
(green): 60.4% (Entropy: 0.758) 
 
Figure 1b: Mean profiles over 1 year from the observed DAS28 data for the MTX-exposed patients 
after stratifying by predicted class membership. Class 1 – Fast Improver Group (red): 9.4%; Class 2 – 
Moderate Improver Group (blue): 43.4%; Class 3 – Inadequate Response Group (green): 47.3% 
(Entropy: 0.609) 
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